Cargando…
Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer
IMPORTANCE: Proton pump inhibitors (PPIs) are commonly used drugs to relieve gastrointestinal tract symptoms, but their acid-inhibitory action negatively affects the bioavailability and clinical outcomes of orally administered concomitant drugs. OBJECTIVE: To identify the clinical outcomes of patien...
Autores principales: | Lee, Ju-Eun, Kwon, Sun-Hong, Kwon, Swan, Jung, Hye-In, Nam, Jin Hyun, Lee, Eui-Kyung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362477/ https://www.ncbi.nlm.nih.gov/pubmed/37477917 http://dx.doi.org/10.1001/jamanetworkopen.2023.24852 |
Ejemplares similares
-
Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
por: Odabas, Hatice, et al.
Publicado: (2023) -
Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Recurrent Stroke and Myocardial Infarction
por: Lee, Yong Kang, et al.
Publicado: (2023) -
Association Between Proton Pump Inhibitor Use During Early Pregnancy and Risk of Congenital Malformations
por: Choi, Ahhyung, et al.
Publicado: (2023) -
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study
por: Eser, Kadir, et al.
Publicado: (2022) -
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer
por: Kawachi, Hayato, et al.
Publicado: (2023)